CCTG

OVC.2

NCT02502266

OVC.2

A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

Status:

Closed to Accrual

26459-200.png

II/III

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Relapsed / Recurrent / Refractory

Disease Stage

Target.png

Biomarker(s)

BRCA1/2

Investigational

Product

Olaparib + Cediranib Maleate

Treatment Arms

o Active Comparator: Phase II Arm I

o Experimental: Phase II Arm II (cediranib maleate, olaparib)

o Experimental: Phase II Arm III (cediranib maleate)

o Experimental: Phase II Arm IV (olaparib)

o Active Comparator: Phase III Arm I (reference regimen)

o Experimental: Phase III Arm II (cediranib maleate, olaparib)

o Experimental: Phase III Arm III (single-agent cediranib maleate)